Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
US12239732B2 · kind B2 · utility
0Cited by
16References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2022 |
| Grant date | Mar 4, 2025 |
| Priority date | — |
| Expiry date | Nov 13, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.